Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:20:56.284Z.
Consensus retrieved: 2026-10-06T09:20:59.377Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:20:56.284Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8e18e4937bb179ad65bb801f5f057f36d78bd2e4af2c39ec5cecdad017acf428
FORWARD PE RATIO
N/A
BriaCell Therapeutics Corp.
Market Cap
$34.97M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| BriaCell Therapeutics Corp. (BCTX) | $34.97M | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.52M | N/A |
| Elutia Inc (ELUT)vs › | $34.35M | N/A |
| DocGo Inc. (DCGO)vs › | $35.76M | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $35.84M | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $35.84M | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $36.21M | 12.12 |
| Scilex Holding Company (SCLX)vs › | $33.63M | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.61M | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.29M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-07-31
Consensus estimates for this stock are reported in USD, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
